en
Scientific article
Open access
English

Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)

Published inBMC Pharmacology & Toxicology, vol. 18, no. 1, 70
Publication date2017
Abstract

It is well known that the standard doses of a given drug may not have equivalent effects in all patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence the burden and costs of mood depressive disorders. The Geneva Cocktail Phenotypic approach presents several advantages including the "in vivo" measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis. The goal of this project is to explore the relationship between the activity of drug-metabolizing enzymes (DME), assessed by a phenotypic approach, and the concentrations of Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV), the efficacy and tolerance of VLX.

Keywords
  • ATP-Binding Cassette
  • Sub-Family B
  • Member 1/metabolism
  • Adolescent
  • Adult
  • Aged
  • Aged
  • 80 and over
  • Antidepressive Agents
  • Second-Generation/blood/pharmacokinetics/therapeutic use
  • Cytochrome P-450 CYP2C19/metabolism
  • Cytochrome P-450 CYP2D6/metabolism
  • Cytochrome P-450 CYP3A/metabolism
  • Depressive Disorder
  • Major/drug therapy/metabolism
  • Female
  • France
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Switzerland
  • Treatment Outcome
  • Venlafaxine Hydrochloride/blood/pharmacokinetics/therapeutic use
  • Young Adult
Citation (ISO format)
LLORET-LINARES, Célia et al. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). In: BMC Pharmacology & Toxicology, 2017, vol. 18, n° 1, p. 70. doi: 10.1186/s40360-017-0173-2
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal2050-6511
370views
147downloads

Technical informations

Creation11/12/2018 3:30:00 PM
First validation11/12/2018 3:30:00 PM
Update time03/15/2023 1:50:39 PM
Status update03/15/2023 1:50:37 PM
Last indexation01/17/2024 4:08:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack